Oxford Biodynamics logo

OBD - Oxford Biodynamics Share Price

55.5p -0.5  -0.9%

Last Trade - 03/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £51.8m
Enterprise Value £36.4m
Revenue £907k
Position in Universe 1045th / 1834
Bullish
Bearish
Unlock OBD Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OBD Revenue Unlock OBD Revenue

Net Income

OBD Net Income Unlock OBD Revenue

Normalised EPS

OBD Normalised EPS Unlock OBD Revenue

PE Ratio Range

OBD PE Ratio Range Unlock OBD Revenue

Dividend Yield Range

OBD Dividend Yield Range Unlock OBD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OBD EPS Forecasts Unlock OBD Revenue
Profile Summary

Oxford BioDynamics Plc is a biotechnology company, which is engaged in biomarker research and development. The Company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. Its geographical segments include UK and Malaysia. Its EpiSwitch is an industrial platform for the discovery, evaluation, validation and monitoring of a class of epigenetic biomarkers known as chromosome conformation signatures (CCSs). EpiSwitch is a biomarker technology platform that facilitates pharmaceutical and biotechnology companies in their therapeutic development programs and the development of companion diagnostics. The EpiSwitch technology has validated biomarkers in a range of diseases, including Alzheimer's disease, breast cancer, ulcerative colitis and liver cancer. Its service offering includes predictive biomarkers, prognostic biomarkers, residual disease monitoring biomarkers, diagnostic biomarkers and companion diagnostic biomarkers.

Directors
Last Annual September 30th, 2019
Last Interim September 30th, 2019
Incorporated April 25, 2007
Public Since December 6, 2016
No. of Shareholders: n/a
No. of Employees: 31
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 92,559,771
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OBD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OBD
Upcoming Events for OBD
Similar to OBD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.